Pfizer Drug Study Falls Short For Alzheimer’s
Lawrence LeBlond for redOrbit.com – Your Universe Online
In one of two late-stage trials conducted by Pfizer, an experimental Alzheimer´s drug failed to slow the disease´s progress, but the pharma said on Monday that it will continue to study the drug´s effect on the other group.
The injected drug bapineuzumab, being tested through a partnership with Johnson & Johnson, didn´t slow mental or functional decline in patients with mild or moderate Alzheimer´s disease, according to Pfizer, which said the trials were marketed at patients carrying the ApoE4 gene, which gives people a greater risk of developing the disease.
Pfizer said that only half of the population carries the ApoE4 gene, yet it is carrying out a study of the drug in patients without the gene as well. Results of that study is expected to be announced later this summer.
The mid-stage tests of the drug gave scientists “a hint that the people who are carriers of the ApoE4 gene might not have as good a chance as people who are not carriers,” Ellen Rose, spokeswoman for Johnson & Johnson, told the Associated Press.
The Phase III drug study is one of four trials being carried out by Pfizer and J&J, both based in New Brunswick, New Jersey. The three other studies will continue as planned, Pfizer said in a statement.
Current drugs on the market for Alzheimer´s offer temporary control of symptoms of the disease, but do nothing to slow, stop or reverse the progression of mental decline.